We’ve welcomed HempFusion (TS:CBD.U) CEO Dr. Jason Mitchell to speak with us at The Dales Report before. We had a great discussion about the company’s regulatory compliance and what things lay in store for the hemp-based CBD company. One of the topics that had come up briefly in that interview was a six-month clinical trial on the effects of CBD on the human body, which HempFusion would be the exclusive brand and sole supplier for. Joining us in this interview is both Dr. Jason Mitchell and Dr. David Harnick, the cardiologist who will be undertaking these clinical trials with HempFusion CBD at Mount Sinai Medical Hospital in NYC.
Here’s some highlights from the interview:
Research on CBD hard to find – but important to pursue say both Harnick and Mitchell
Part of what has been driving both doctors’ interest in these clinical trials is the lack of clinical research on cannabis, THC, and CBD. Dr. Harnick said, “There’s a lot of anecdotal [evidence] about how it affects your neuropsychiatric system and how it might effect pain systems, and how it’s used as a drug for the one condition that it’s approved for is seizures.” But controlled studies on how it impacts cardiovascular systems is limited.
Dr. Mitchell, whose experience with CBD has a more personal beginning, says that in seeking treatment for his own condition, he learned a great deal about the medical mysteries that still exist and which still elude medical professionals – things that CBD may be able to affect, as there’s a great deal unknown about the human endocannabinoid system, which controls homeostasis. “Every biological system in the body is affected by the endocannabinoid system,” he says, “and plant-based cannabinoids affect the entire endocannabinoid system in one way or another. It’s absolutely amazing and I think uncovering this is important.”
Clinical Trial run by Dr Harnick to be a randomized, double-blind placebo-controlled trial
Dr. Harnick wants to eliminate some of the anecdotal ‘evidence’ about the properties of CBD and replace them with facts in this upcoming clinical trial. The double-blind placebo-controlled trial, he says, is the best way to eliminate both external bias and the placebo effect.
As far as outcomes, Dr. Harnick says that any beneficial results, of course, are great. But even a neutral study where patients feel better might still be a good outcome. Still, he emphasizes that this is an early first step in understanding both CBD and the effect it might have on the body.
Conversations improving about the possibilities of medical value in CBD – meaning great things for investors
Both doctors have come from initial skepticism about CBD and cannabis to seeing value. Dr. Mitchell says that when he was in medical school, they didn’t teach about the endocannabinoid system, and even still it’s poorly understood. Dr. Harnick agrees that both he and other doctors want to have the answers about CBD, rather than not having an answer or suggesting that patients ‘go try it.’
Dr. Mitchell believes that these clinical trials and understanding more about regulatory homeostasis in the human body could be part of the beginning of an entire group in medicine called endocannabinologists, and his hope is that learning continues. “We’re absolutely committed to the long game. … Hempfusion is not only involved in creating great products for the retail community or the online community, but that in fact we’re committed to research that will further … this industry as a whole and then medicine that we will hopefully contribute to.”